| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-04-27 | Zinforo® (ceftaroline fosamil) | complicated skin and soft tissue infections (cSSTI) |
3 | AstraZeneca (UK) | Infectious diseases |
| 2015-04-27 | ceftazidime/avibactam (CAZ-AVI) | Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections | 3 | AstraZeneca (UK) Forest Laboratories (USA - NJ), an Actavis' subsidiary (Ireland) | Infectious diseases |
| 2015-04-27 | SYN-005 | pertussis |
preclinical | Synthetic Biologics (USA - MD) | Infectious diseases |
| 2015-04-27 | TXA709 | multidrug-resistant bacteria infections |
preclinical | Taxis Pharmaceuticals (USA - NJ) | Infectious diseases |
| 2015-04-27 | lonafarnib | hepatitis delta viral (HDV) infection |
2 | Eiger Biopharmaceuticals (USA - CA) | Infectious diseases |
| 2015-04-27 | AUT00063 | age related hearing loss |
2a | Autifony Therapeutics (UK) | Otorhinolaryngology |
| 2015-04-26 | CF602 | sexual dysfunction |
preclinical | Can-Fite BioPharma (Israel) | |
| 2015-04-26 | CF101 | glaucoma |
2 | Can-Fite BioPharma (Israel) OphthaliX (USA - NY) | Ophtalmological diseases |
| 2015-04-26 | Mydicar® | advanced heart failure | 2b | Celladon (USA - CA) | Cardiovascular diseases |
| 2015-04-25 | RG-101 | hepatitis C | 1 | Regulus Therapeutics (USA - CA) | Infectious diseases |
| 2015-04-25 | daclatasvir and sofosbuvir | chronic hepatitis C |
3 | BMS (USA - NY) | Infectious diseases |
| 2015-04-24 | RTS,S/AS01 | malaria |
3 | PATH Malaria Vaccine Initiative (MVI), GSK (UK), Agenus (USA - MA) | Infectious diseases - Parasitic diseases |
| 2015-04-24 | Dalvance® (dalbavancin) | Gram-positive acute bacterial skin and skin structure infections (ABSSSI) |
3b | Actavis (Ireland) | Infectious diseases |
| 2015-04-24 | BLU-554 | hepatocellular carcinoma | preclinical | Blueprint Medicines (USA - MA) | Cancer - Oncology |
| 2015-04-23 | MIV-802 | hepatitis C | preclinical | Medivir (Sweden) | Infectious diseases |
| 2015-04-23 | ornithine transcarbamylase deficiency | Dimension Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Metabolic diseases | ||
| 2015-04-23 | glycogen storage disease type Ia (GSDIa) | Dimension Therapeutics (USA - MA) | Rare diseases - Genetic diseases | ||
| 2015-04-23 | laquinimod | primary progressive multiple sclerosis | 2 | Teva Pharmaceutical Industries (Israel) Active Biotech (Sweden) | Autoimmune diseases - Neurodegenerative diseases |
| 2015-04-23 | ARGX-115 | preclinical | arGEN-X (The Netherlands - Belgium) de Duve Institute/UCL (Belgium) | Cancer - Oncology | |
| 2015-04-23 | solid dose formulation of teriparatide (parathyroid hormone) | osteoporosis |
preclinical | Glide Technologies (UK) | Bone diseases |
